● British start-up Clerkenwell Health, Europe’s first commercial psychedelic clinical trials facility, and brain wellness and analytics company MYndspan, are partnering to advance the application of psychedelics in medicine ● Psychedelics researchers running trials at Clerkenwell Health’s new London site will have access to MYndspan’s non-invasive brain scanning technology ● This first-of-its-kind…

Source

Previous articleMIND CURE CLOSES PREVIOUSLY ANNOUNCED PRIVATE PLACEMENT
Next articleSunstone Therapies to present data on the long-term efficacy of psilocybin therapy in cancer patients with major depressive disorder (MDD) at the ASCO 2023 Annual Meeting